Merck: Keytruda Combo Meets Main Endpoint in Metastatic Triple-Negative Breast Cancer
February 12 2020 - 6:42AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Wednesday said a phase 3 study of its cancer
drug Keytruda in combination with chemotherapy met one of its dual
primary endpoints in a form of triple-negative breast cancer.
The Kenilworth, N.J., drug maker said the combination showed a
statistically significant and clinically meaningful improvement in
progression-free survival in patients with metastatic
triple-negative breast cancer whose tumors expressed PD-L1.
Merck said the study will continue without changes to evaluate
the other primary endpoint of overall survival.
The company said Keytruda's safety profile in the trial was
consistent with previous studies, with no new safety signals
identified.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 12, 2020 07:27 ET (12:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024